Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.5369 USD
−29.49 M USD
0.00 USD
37.04 M
About Tempest Therapeutics, Inc.
Sector
CEO
Stephen R. Brady
Headquarters
Brisbane
Website
Founded
2011
FIGI
BBG002NDK339
Tempest Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company was founded in 2011 and is headquartered in Brisbane, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of TPST is 0.9404 USD — it has increased by 1.06% in the past 24 hours. Watch Tempest Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Tempest Therapeutics, Inc. stocks are traded under the ticker TPST.
TPST stock has risen by 5.33% compared to the previous week, the month change is a −13.67% fall, over the last year Tempest Therapeutics, Inc. has showed a −75.76% decrease.
We've gathered analysts' opinions on Tempest Therapeutics, Inc. future price: according to them, TPST price has a max estimate of 47.00 USD and a min estimate of 5.00 USD. Watch TPST chart and read a more detailed Tempest Therapeutics, Inc. stock forecast: see what analysts think of Tempest Therapeutics, Inc. and suggest that you do with its stocks.
TPST reached its all-time high on Mar 25, 2015 with the price of 12,523.9849 USD, and its all-time low was 0.1700 USD and was reached on Oct 10, 2023. View more price dynamics on TPST chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
TPST stock is 8.16% volatile and has beta coefficient of 3.51. Track Tempest Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Tempest Therapeutics, Inc. there?
Today Tempest Therapeutics, Inc. has the market capitalization of 41.04 M, it has increased by 0.42% over the last week.
Yes, you can track Tempest Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Tempest Therapeutics, Inc. is going to release the next earnings report on Mar 19, 2025. Keep track of upcoming events with our Earnings Calendar.
TPST earnings for the last quarter are −0.41 USD per share, whereas the estimation was −0.36 USD resulting in a −13.26% surprise. The estimated earnings for the next quarter are −0.25 USD per share. See more details about Tempest Therapeutics, Inc. earnings.
Tempest Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
TPST net income for the last quarter is −10.56 M USD, while the quarter before that showed −9.57 M USD of net income which accounts for −10.30% change. Track more Tempest Therapeutics, Inc. financial stats to get the full picture.
No, TPST doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 27, 2024, the company has 17.00 employees. See our rating of the largest employees — is Tempest Therapeutics, Inc. on this list?
Like other stocks, TPST shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Tempest Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Tempest Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Tempest Therapeutics, Inc. stock shows the sell signal. See more of Tempest Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.